Conv. Plasma
Nigella Sativa
Peg.. Lambda

All favipiravir studies
Meta analysis
Home COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  

The efficacy and adverse effects of favipiravir on COVID-19 patients: a systematic review and meta-analysis of published clinical trials and observational studies

Hung et al., SSRN, doi:10.2139/ssrn.3889346
Apr 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
Systematic review and meta analysis of 17 favipiravir trials, showing improved viral clearance and recovery.
Currently there are 66 favipiravir studies and meta analysis shows:
Mortality14% lower [-1‑28%]
Ventilation8% higher [-25‑54%]
ICU admission30% higher [9‑55%]
Hospitalization4% higher [-12‑24%]
Hung et al., 22 Apr 2022, peer-reviewed, 23 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies
Dang The Hung, Suhaib Ghula, Jeza Muhamad Abdul Aziz, Abdelrahman M Makram, Gehad Mohamed Tawfik, Ali Ahmed-Fouad Abozaid, Rohan Andrew Pancharatnam, Amr Mohamed Ibrahim, Muhammad Besher Shabouk, Morgan Turnage, Saloni Nakhare, Zahra Karmally, Basel Kouz, Tran Nhat Le, Suleiman Alhijazeen, Nguyen Quoc Phuong, Alaa Mohamed Ads, Ali Hussein Abdelaal, Nguyen Hai Nam, Tatsuo Iiyama, Kyoshi Kita, Kenji Hirayama, Nguyen Tien Huy
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.04.035
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Ethical Approval: This study is exempt from ethical approval. Conflict of interest We declare no competing interests.
Agrawal, Raju, Udwadia, Favipiravir: A new and emerging antiviral option in COVID-19, Medical journal, Armed Forces India
Aleem, Kj, Remdesivir, None, StatPearls
Atallah, Hamour, Mallah, Bonilla, Bader, Traveling for heart transplantation and returning with COVID-19: a logistical, clinical, and pharmacotherapeutic challenge from the Middle East, Drugs Ther Perspect
Atkins, Best, Briss, Eccles, Falck-Ytter et al., Grading quality of evidence and strength of recommendations, BMJ (Clinical research ed
Balykova, Govorov, Vasilyev, Simakina, Agafyina et al., Characteristics of covid-19 and possibilities of early causal therapy. Results of favipiravir use in clinical practice, Infektsionnye Bolezni 2020a
Balykova, Granovskaya, Zaslavskaya, Simakina, Agaf'ina et al., New possibilities for targeted antiviral therapy for COVID-19. Results of a multi center clinical study of the efficacy and safety of using the drug Areplivir, Infectious diseases: News, Opinions, Training 2020b
Balykova, Pavelkina, Shmyreva, Pyataev, Selezneva et al., EFFICACY AND SAFETY OF SOME ETIOTROPIC THERAPEUTIC SCHEMES FOR TREATING PATIENTS WITH NOVEL CORONAVIRUS INFECTION (COVID-19), Pharmacy & Pharmacology-Farmatsiya I Farmakologiya
Bayram, Yildirim, Ozmen, Soylu, Dundar et al., Elevation of Serum Transaminase Levels Due to Favipiravir Use in the Treatment of COVID-19, Cureus
Bosaeed, Alharbi, Altayib, Albayat, Alharbi, Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial, Infectious diseases and therapy
Cai, Yang, Liu, Chen, Shu et al., Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study, Engineering
Chen, Huang, Cheng, Wu, Chen et al., Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial, medRxiv
Chen, Zhang, Huang, Yin, Cheng et al., Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
Chuah, Chow, Hor, Cheng, Ker et al., Efficacy of Early Treatment with Favipiravir on Disease Progression among High Risk COVID-19 Patients: A Randomized, Open-Label Clinical Trial, Clin Infect Dis
Deeks, Hj ; Doi, Hibino, Hase, Yamamoto et al., A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19
Enoki, Igarashi, Watabe, Honma, Suzuki et al., Remdesivir for the treatment of coronavirus COVID-19: A meta-analysis of randomised controlled trials, J Glob Antimicrob Resist
Finberg, Ashraf, Julg, Ayoade, Marathe et al., US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19, Open Forum Infect Dis
Gandhi, Yokoe, Havlir, Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control COVID-19, The COVID
Goyal, Cardozo-Ojeda, Schiffer, Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response, Science advances
Guedj, Piorkowski, Jacquot, Madelain, Nguyen et al., Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques, PLoS Med
Han, Fan, Alwalid, Li, Jia et al., Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia, Radiology
Hase, Kurata, Ishida, Kurita, Muranaka et al., Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019, Internal medicine
Hassanipour, Arab-Zozani, Amani, Heidarzad, Fathalipour et al., The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and metaanalysis of clinical trials, Sci Rep
Higgins, Altman, Gotzsche, Juni, Moher et al., The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, BMJ
Holubar, Subramanian, Purington, Hedlin, Bunning et al., Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial, J Clin Exp
Hopkins, Coronavirus Resource Center
Irie, Nakagawa, Fujita, Tamura, Eto et al., Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19, Clin Transl Sci
Ivashchenko, Dmitriev, Vostokova, Azarova, Blinow et al., AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial, Clin Infect Dis
Jiang, Chen, Cai, Yi, Jiang, Effectiveness of remdesivir for the treatment of hospitalized COVID-19 persons: A network meta-analysis, J Med Virol
Kaneko, Kurosaki, Nagata, Taki, Ueda et al., Liver injury with COVID-19 based on gastrointestinal symptoms and pneumonia severity, PLoS One
Karatas, Aksoy, Kilic, Dogru, Ozaslan et al., Favipiravir Induced Acute Pancreatitis in a COVID-19 Patient, Journal of Medicine
Kayiran, Cebeci, Erdemir, Aksoy, Akdeniz et al., Fluorescence of nails and hair on Wood's lamp examination in Covid Pandemic; undefined effect of Favipiravir in humans, Dermatol Ther
Koba, Yoneda, Kaneda, Ueda, Kimura et al., Severe coronavirus disease 2019 (COVID-19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series, Clin Case Rep
Kocayigit, Suner, Tomak, Demir, Yaylaci et al., Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19, J Clin Pharm Ther
Koseki, Nakajima, Iwasaki, Yamada, Takahashi et al., Baseline uric acid levels and steady-state favipiravir concentrations are associated with occurrence of hyperuricemia among COVID-19 patients, International Journal of Infectious Diseases
Kurita, Ishida, Muranaka, Sasazawa, Mito et al., A Favipiravir-induced Fever in a Patient with COVID-19, Internal medicine
Lou, Liu, Yao, Hu, Su et al., Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial, Eur J Pharm Sci
Lowe, Brown, Chowdhury, Davey, Yee et al., Favipiravir, lopinavirritonavir or combination therapy (FLARE): a randomised, double blind, 2x2 factorial placebocontrolled trial of early antiviral therapy in COVID-19, BMC Infectious Diseases
Musekiwa, Manda, Mwambi, Chen, Meta-analysis of effect sizes reported at multiple time points using general linear mixed model, PloS one
Nasa, Shrivastava, Kulkarni, Vijayan, Singh, Favipiravir Induced Nephrotoxicity in Two Patients of COVID-19
Nguyen, Guedj, Anglaret, Laouenan, Madelain et al., Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted, PLoS neglected tropical diseases
Ono, Kishimoto, Shimasaki, Uchida, Kurai et al., Reactive arthritis after COVID-19 infection, RMD Open
Page, Mckenzie, Bossuyt, Boutron, Hoffmann et al., The PRISMA 2020 statement: an updated guideline for reporting systematic reviews, BMJ
Perveen, Nasir, Murshed, Naznin, Ahmed, Remdesivir and Favipiravir Changes Hepato-Renal Profile in COVID-19 Patients: A Cross Sectional Observation in Bangladesh, International Journal of Medical Science and Clinical Invention
Piscoya, Ng-Sueng, Del Riego, Cerna-Viacava, Pasupuleti et al., Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis, PLoS One
Prakash, Singh, Kaur, Semwal, Sarma et al., Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients, Indian J Pharmacol
Pushkar, Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
Rattanaumpawan, Jirajariyavej, Lerdlamyong, Palavutitotai, Saiyarin, Real-world Experience with Favipiravir for Treatment of COVID-19 in Thailand: Results from a Multicenter Observational Study, medRxiv
Rong, Wang, Tian, Liang, Wang et al., Clinical and CT features of mild-tomoderate COVID-19 cases after two sequential negative nucleic acid testing results: a retrospective analysis, BMC Infect Dis
Rubin, Chan-Tack, Farley, Sherwat, FDA Approval of Remdesivir -A Step in the Right Direction, The New England journal of medicine
Ruzhentsova, Chukhliaev, Khavkina, Garbuzov, Oseshnyuk et al., Phase 3 Trial of Coronavir (Favipiravir) in Patients with Mild to Moderate COVID-19, SSRN Electronic Journal
Ruzhentsova, Oseshnyuk, Soluyanova, Dmitrikova, Mustafaev et al., Phase 3 trial of coronavir (favipiravir) in patients with mild to moderate COVID-19, American journal of translational research
Sarohan, Akelma, Arac, Aslan, Shannon et al., Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis, Nat Commun
Shenoy, Munjal, Youha, Alghounaim, Almazeedi et al., Favipiravir In Adults with Moderate to Severe COVID-19: A Phase 3 Multicentre, Randomized, Double-Blinded, Placebo-Controlled
Shinkai, Tsushima, Tanaka, Hagiwara, Tarumoto et al., Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial, Infectious diseases and therapy
Shiraki, Daikoku, Favipiravir, an anti-influenza drug against life-threatening RNA virus infections, Pharmacol Ther
Shrestha, Budhathoki, Khadka, Shah, Pokharel et al., Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and metaanalysis, Virology journal
Solaymani-Dodaran, Ghanei, Bagheri, Qazvini, Vahedi et al., Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia, Int Immunopharmacol
Sterne, Hernan, Reeves, Savovic, Berkman et al., ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Tabarsi, Vahidi, Saffaei, Hashemian, Jammati et al., Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form, Iranian journal of pharmaceutical research
Takoi, Togashi, Fujimori, Kaizuka, Otsuki et al., Favipiravir-induced fever in coronavirus disease 2019: A report of two cases, Int J Infect Dis
Takumida, Izumi, Sakamoto, Hashimoto, Ishii et al., Sustained coronavirus disease 2019-related organizing pneumonia successfully treated with corticosteroid, Respir Investig
Tawfik, Dila, Mohamed, Tam, Kien et al., A step by step guide for conducting a systematic review and meta-analysis with simulation data, Trop Med Health
Udwadia, Singh, Barkate, Patil, Rangwala et al., Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial, Int J Infect Dis
Uçan, Çerçi, Efe, Akgün, Özmen et al., Benefits of Treatment With Favipiravir in Hospitalized Patients for COVID-19: a Retrospective Observational Case-control Study, Virology journal
Vitiello, Porta, 'aiuto, Ferrara, The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced, Egyptian Liver Journal
Wan, Wang, Liu, Tong, Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range, BMC medical research methodology
Yamazaki, Suzuki, Sayama, Nakada, Igari et al., Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19, J Infect Chemother
Yaylaci, Dheir, Senocak, Genc, Kocayigit et al., The effects of favipiravir on hematological parameters of covid-19 patients, Rev Assoc Med Bras
Yilmaz, Güner, Altuntas, Results of Favipiravir Combined Treatment in Intensive Care Patients With Covid-19
Yokoyama, Briasoulis, Takagi, Kuno, Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials, Virus Res
Zhao, Zhang, Zhu, Chen, Chen et al., Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial, Int Immunopharmacol
Zhao, Zhu, Zhang, Li, Wei et al., Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size, Biomed Pharmacother
Zhu, Chen, Gorshkov, Xu, Lo et al., RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery, SLAS Discov
Çap, Bilge, Işık, Burak, Karagöz et al., The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019, J Electrocardiol
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop